Banque Pictet & Cie Sa Fate Therapeutics Inc Transaction History

Banque Pictet & Cie Sa

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$21.04 - $36.06 $3,492 - $5,985	-166 Reduced 0.37%	44,394 $995 Million
Q2 2022 Aug 08, 2022	SELL	$17.78 - $42.39 $76,365 - $182,065	-4,295 Reduced 8.79%	44,560 $1.1 Million
Q1 2022 May 04, 2022	BUY	$29.67 - $60.28 $56,165 - $114,110	1,893 Added 4.03%	48,855 $1.89 Million
Q4 2021 Feb 02, 2022	BUY	$47.84 - $64.34 $2.25 Million - $3.02 Million	46,962 New	46,962 $2.75 Million

176

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $123M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.